Diabetic Neuropathy, Painful Clinical Trial
— REGAiN-1AOfficial title:
An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Engensis in Participants With Painful Diabetic Peripheral Neuropathy
Verified date | November 2022 |
Source | Helixmith Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the efficacy and safety of intramuscular (IM) administration of Engensis on pain in participants with painful diabetic peripheral neuropathy (DPN) in the feet and lower legs, as compared to Placebo, as a second Phase 3, well controlled study, sufficient in supporting the efficacy and safety of Engensis.
Status | Active, not recruiting |
Enrollment | 160 |
Est. completion date | June 30, 2023 |
Est. primary completion date | March 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria 1. Male or female participants age = 18 years at time of completion of the informed consent process 2. Type 1 or 2 diabetes mellitus (DM) and on current Standards of Medical Care in Diabetes - 2020 optimal guideline-directed medical therapy in participants (including vaccine recommendations if possible), AND without unstable diabetes or significant medical problems, such as progressive end-organ disease, within 3 months of or during Screening, in the judgment of the Investigator 3. Glycosylated hemoglobin A1c (HbA1c) of = 10.0% using the first assessment collected during Screening 4. Documented diagnosis of bilateral painful DPN in both lower extremities at least 6 months prior to Screening 5. An Average Daily Pain Score = 4 (standard deviation = 0.3 and = 1.5) that is completed during the 7 days prior to randomization (Day 0) 6. The physical examination component of the Michigan Neuropathy Screening Instrument (MNSI) score of = 2.5 7. If on medication for painful DPN (other than gabapentin or pregabalin), must be on a stable dose defined as < 50% change in total dose over 3 months prior to completion of informed consent process 8. Male participants and their female partners must agree to use double-barrier contraception during the study or provide proof of postmenopausal state (minimum 1 year) or surgical sterility 9. Male participants must not donate sperm during the study 10. Female participants must be nonpregnant, nonlactating, and either postmenopausal for at least 1 year, or surgically sterile for at least 3 months, or agree to use double barrier contraception from 28 days prior to randomization and/or their last confirmed menstrual period prior to study randomization (whichever is longer) until the end of the study 11. Capable and willing to comply with the requirements and restrictions of the protocol and informed consent form 12. Able to complete all screening activities within 45 days of signing the informed consent form Exclusion Criteria 1. Other sources of pain that would prevent accurate assessment of DPN pain (e.g., thoracic and/or lumbar root proximal neuropathy, mononeuritis multiplex) 2. Peripheral neuropathy caused by a condition other than diabetes: e.g., anatomic (sciatic nerve compression), systemic (monoclonal gammopathy), metabolic (thyroid disease), and toxic (alcohol use) neuropathies 3. Has taken gabapentin or pregabalin during 30 days before completion of informed consent process or will take at any time during the study 4. Progressive or degenerative neurological disorder, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, vascular dementia, multiple sclerosis, or other neurological disorders determined by the Investigator to preclude participation 5. Symptomatic peripheral artery disease (PAD) or PAD requiring revascularization and/or that may interfere with the conduct of the study 6. Vasculitis, such as from Buerger's or other disease 7. Systolic blood pressure >180 mm Hg on tolerable doses of standard antihypertensive medications at Screening determined by the Investigator to preclude participation 8. Hyperlipidemia or dyslipidemia not being treated with an optimal treatment regimen that follows the Standards of Care for hyperlipidemic/dyslipidemic patients with DM 9. Class 3 or 4 heart failure 10. Symptomatic bradycardia or untreated high degree atrioventricular block 11. Stroke or cerebrovascular accident or myocardial infarction within 3 months before Screening 12. eGFR < 30 mL/min/1.73 m2 13. Progressive renal dysfunction, defined as a decrease in eGFR to chronic kidney disease (CKD) Stage 1, 2, or 3 in the past 6 months before Screening 14. Ophthalmologic conditions pertinent to signs or symptoms of proliferative diabetic retinopathy (PDR) or other ocular conditions that preclude standard ophthalmologic examination 15. Myopathy (e.g., Duchenne or Becker muscular dystrophy, polymyositis) 16. Any prior or planned lower extremity amputation (excluding toe amputations) due to diabetic complications or prior lower leg injury (e.g., scarring, muscle atrophy) in the calf area (gastrocnemius) that would significantly reduce the surface area of the skin or amount of intact skeletal muscle required for the 16 treatment injections of Engensis 17. Active infection requiring antimicrobial agent(s) (chronic infection or severe active infection that may compromise the Participant's well-being or participation in the study, in the Investigator's judgment) 18. Chronic inflammatory or autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis) 19. Immunosuppression due to underlying disease (e.g., rheumatoid arthritis, systemic lupus erythematosus) or to currently receiving immunosuppressive drugs, (e.g., chemotherapy, corticosteroids) or to radiation therapy 20. Participants requiring chronic oral or injectable steroids and unwilling to refrain from taking these drugs for the duration of the study 21. Participants with a family medical history of 2 or more first-degree relatives (parent, sibling, child) diagnosed to have the same type of cancer - breast cancer, cervical cancer, colon cancer, endometrial cancer, lung cancer, or prostate cancer, or with a family medical history of Lynch syndrome (hereditary non-polyposis colorectal cancer) in any first-degree relative; or who show positive results during cancer screening 22. Positive human immunodeficiency virus (HIV) or human T-cell lymphotropic virus (HTLV) I/II test at Screening 23. Participants who have not been cancer-free for = 5 years with the following exceptions (not excluded): Participants with in-situ basal cell or squamous cell carcinoma 24. Participants with a prior history of stem cell transplant for cancer no matter how long they have been cancer-free 25. Active acute or chronic hepatitis B 26. Active hepatitis C 27. Clinically significant laboratory values or current medical conditions during Screening that, in the judgment of the Investigator, should be exclusionary 28. Hospital Anxiety and Depression Scale (HADS) score of = 15 on either subscale 29. History of drug abuse (the habitual taking of addictive or illegal drugs) in the past 3 months and positive for Drugs of Abuse, with the exception of cannabis, during Screening 30. Participants unwilling to discontinue their use of the following during Screening at least 7 days before starting eDiary entries and not use any of the following during the study: - skeletal muscle relaxants - opioids - transcutaneous electrical nerve stimulation (TENS) - acupuncture - benzodiazepines (other than stable bedtime dose) - injectable or oral steroids 31. Participants not on a stable dose and not willing to remain on a stable dose during the study for the following drugs: - antidepressants - antiepileptics - duloxetine 32. Participants currently using the following medications and unwilling to discontinue topical use on the lower legs and feet and throughout the study: - capsaicin - anesthetic creams (except during Study Injections) - anesthetic patches - ISDN spray 33. Use of an investigational drug or treatment in past 30 days or previous participation in a clinical study with Engensis 34. Body mass index (BMI) = 42 kg/m2 35. Recent treatment for COVID-19 with ongoing sequelae |
Country | Name | City | State |
---|---|---|---|
United States | Clinical Research Professionals | Chesterfield | Missouri |
United States | Innovative Research of West Florida, Inc. | Clearwater | Florida |
United States | Nerve and Muscle Center of Texas | Houston | Texas |
United States | Clinical Trials - Little Rock | Little Rock | Arkansas |
United States | California Medical Clinic for Headache | Los Angeles | California |
United States | Manassas Clinical Research Center | Manassas | Virginia |
United States | Futuro Clinical Trials | McAllen | Texas |
United States | Eastern Virginia Medical School | Norfolk | Virginia |
United States | Gateway Clinical Trials, LLC | O'Fallon | Illinois |
United States | Arizona Research Center | Phoenix | Arizona |
United States | Health Concepts | Rapid City | South Dakota |
United States | Dominion Medical Associates | Richmond | Virginia |
United States | Clinical Trials Research - Sacramento | Sacramento | California |
United States | Foot & Ankle Center of Illinois | Springfield | Illinois |
United States | Richmond Behavioral Associates | Staten Island | New York |
United States | ClinPoint Trials LLC | Waxahachie | Texas |
Lead Sponsor | Collaborator |
---|---|
Helixmith Co., Ltd. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | To determine whether IM administration of Engensis has the potential for disease modification by measuring the improvement in Bedside Sensory Testing at Day 180 compared to Baseline | • The Bedside Sensory Testing scale has a minimum score of 0 and a maximum score of 10 with a higher score representing a better outcome | 180 days | |
Other | To determine whether IM administration of Engensis has the potential for improving quality of life, sensation, proprioception, and deep tendon reflexes by measuring the improvement in Bedside Sensory Testing at Day 180 compared to Baseline | • The Bedside Sensory Testing scale has a minimum score of 0 and a maximum score of 10 with a higher score representing a better outcome | 180 days | |
Primary | Efficacy of Engensis compared to Placebo on painful DPN in the feet and lower legs comparing the Average Daily Pain Score from the Day 0 Visit to the Day 180 Visit on the Brief Pain Inventory for Participants with Diabetic Peripheral Neuropathy | • The Brief Pain Inventory for Participants with Diabetic Peripheral Neuropathy has a minimum score of 0 and a maximum score of 10, with a higher score representing a worse outcome of more pain. | 180 days | |
Secondary | Efficacy of Engensis on the worst pain in painful DPN in the feet and lower legs by comparing the change from baseline (Day 0) in the Worst Pain score from the Brief Pain Inventory for Diabetic Peripheral Neuropathy to Day 180 compared to Placebo | • The Brief Pain Inventory for Diabetic Peripheral Neuropathy (BPI-DPN) has a minimum score of 0 and a maximum score of 10, with a higher score representing a worse outcome of more pain | 180 days | |
Secondary | Efficacy of Engensis on reducing pain in painful DPN in the feet and lower legs by determining a = 50% reduction in the Average Daily Pain Score from baseline to Day 180 using the Brief Pain Inventory for Participants with Diabetic Peripheral Neuropathy | • The Average Daily Pain Score from the Brief Pain Inventory for Participants with Diabetic Peripheral Neuropathy has a minimum score of 0 and a maximum score of 10 with a higher score representing a worse outcome of more pain | 180 days | |
Secondary | Safety of Engensis in painful DPN in the feet and lower legs by comparing the incidence of adverse and serious adverse events, the incidence of injection site reactions, and the incidence of clinically significant laboratory values to Placebo | Incidence of adverse events (AEs) and serious adverse events (SAEs)
Incidence of injection site reactions Incidence of clinically significant laboratory values |
180 days | |
Secondary | To evaluate the possibility of cellular responses to Engensis | • Change from baseline in the TNF-alpha, IL-1b, IFNy, IL-6, IL-4, IL-10, and IL-12p70 cytokine profile post-dose at the Day 104 visit | 104 days | |
Secondary | To evaluate the possibility of humoral responses to Engensis | • Presence of hepatocyte growth factor (HGF) antibodies | 104 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04988321 -
Theta Burst Brain Stimulation in Diabetic Neuropathy Patients With Neuropathic Pain: Investigating Neural Mechanisms
|
N/A | |
Completed |
NCT00385671 -
An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain
|
Phase 4 | |
Completed |
NCT00159679 -
Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
|
Phase 4 | |
Completed |
NCT00141401 -
Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.
|
Phase 3 | |
Completed |
NCT00553475 -
Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
|
Phase 3 | |
Completed |
NCT00381719 -
Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT00539175 -
Treatment of Painful Diabetic Neuropathy With Photon Stimulation
|
N/A | |
Completed |
NCT00058968 -
A Study for the Treatment of Painful Diabetic Neuropathy
|
Phase 3 | |
Completed |
NCT05029297 -
Study With Two Capsaicin Topic Treatments in Diabetic Neuropathy.
|
Phase 3 | |
Completed |
NCT02215252 -
A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)
|
Phase 2 | |
Completed |
NCT00785577 -
A Study for Treatment of Pain in Patients With Diabetic Neuropathy.
|
Phase 2 | |
Completed |
NCT00858351 -
Thermal Biofeedback for the Treatment of Diabetic Neuropathy
|
N/A | |
Completed |
NCT03047278 -
Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain.
|
Phase 4 | |
Completed |
NCT01628627 -
Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy
|
Phase 4 | |
Completed |
NCT03315598 -
Evaluation of an Effectiveness and Safety of the Electroacupuncture in the Management of Intractable Neuropathic Pain
|
N/A | |
Completed |
NCT01057693 -
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
|
Phase 3 | |
Completed |
NCT01564459 -
Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)
|
Phase 2 | |
Recruiting |
NCT01214590 -
Preliminary Assessment of the Efficacy of the VascuActive™ Device on Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT01089556 -
A Study in Painful Diabetic Neuropathy
|
Phase 3 | |
Completed |
NCT00501202 -
Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).
|
Phase 2 |